11-Mar-2014 - Pfizer’s $3.5m expansion of an Indonesian solid oral dose plant will increase capacity by 76%, the company says.
05-Mar-2014 - Addiction doctors have petitioned the US FDA to prevent Zohydro ER, the first single-entity hydrocodone painkiller, hitting the market this month citing its potential for abuse. Its maker, Zogenix, has been tight-lipped on whether the drug’s formulation uses anti-abuse technology.
27-Feb-2014 - European regulators have been accused of making “no attempt” to counter misuse of prescription drugs in comparison with North American efforts to reformulate and restrict addictive drugs, according to a Canadian firm testing the abuse potential of medicines.
26-Feb-2014 - Cellceutix has selected Dr. Reddy’s Custom Pharmaceutical Services (CPS) for the formulation of its defensin mimetic drug Brilacidin for use in ophthalmic and otitis infections.
25-Feb-2014 - The US FDA on Monday announced in a draft guidance that it’s revising its historical interpretation of the 5-year NCE exclusivity provisions to further incentivize the development of certain fixed-combination products.
18-Feb-2014 - Debate rages over the significance of safety data from a trial of Oramed’s oral insulin pill, but the firm is still confident in its delivery technology.
18-Feb-2014 - Actavis has confirmed it will acquire Forest Laboratories in a deal worth up to $25bn (€18bn) following rumours last night.
11-Feb-2014 - The National Institutes of Health and 10 pharmaceutical companies have launched a partnership to transform the current model for identifying and validating promising biological targets for Type 2 diabetes, Alzheimer’s disease, lupus and rheumatoid arthritis.
10-Feb-2014 - Pfizer says its ‘off the shelf’ aseptic processing capacity is shifting the paradigm of pharma manufacturing, with emerging markets and personalised medicine driving the change.
04-Feb-2014 - Novozymes Biopharma has confirmed that two “top 10” pharmaceutical firms are using its modified human albumin in their drug development programmes.
03-Feb-2014 - Novartis has confirmed that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year.
03-Feb-2014 - Lupin Ltd has bought Dutch delivery technology company Nanomi BV in a deal that moves the Indian generics firm into the complex injectables space.
30-Jan-2014 - Clarus Therapeutics has submitted to the FDA a testosterone replacement it claims overcomes the toxicity problems that have plagued other oral drugs like methyltestosterone.
30-Jan-2014 - Increasing demand for HPAPIs has driven Patheon to invest in its Milton Park, UK manufacturing facility, the company says.
27-Jan-2014 - Actavis has announced plans to sell its stake in its Chinese subsidiary just days after telling investors the country is 'too risky' for new investments.
23-Jan-2014 - Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
16-Jan-2014 - Complex generics will represent over 50% of Teva’s generic market by 2017, the firm says, but investments in delivery technology will have positive implications across the full business.
15-Jan-2014 - Drugs containing APIs derived from cannabis plants are a far cry from the non-clinical approach of marijuana dispensaries, says GWPharma, as France approves Sativex.
09-Jan-2014 - Marine bacteria may yield the next generation of MRSA fighting drugs according to a team that used a peptide from a Pacific Ocean bug to render the hospital superbug less lethal.
09-Jan-2014 - A drug delivery technology that ‘shuttles’ molecules across the blood-brain-barrier could have major implications in developing drugs for disorders such as Alzheimer's and Parkinson’s disease, Roche says.
Dow’s AFFINISOL™ line of excipients include AFFINISOL™ HMPCAS for spray drying applications and AFFINISOL™ HPMC for hot melt extrusion...
How glass-forming polymers improve bioavailabilityPolymers are essential components of oral solid dosage forms and used...
Most new drug candidates suffer from poor water- solubility leading to rate limiting dissolution, slow absorption and limited bioavail...